<DOC>
	<DOCNO>NCT02220114</DOCNO>
	<brief_summary>The sponsor develop new paediatric formulation vigabatrin well adjust dose body weight limit waste unused drug . The currently market vigabatrin ( Sabril™ ) form exist 500 mg film coat tablet ( adult child 6 year ) 500 mg granule oral solution sachet ( infant child 6 year ) . Sabril™ adapt administration infant fraction sachet need . Manual splitting sachet lengthy error-prone dilution often require . This study descriptive , non-randomized , open label multi-centric acceptability study infant child affect infantile spasm . The primary objective describe adherence new formulation . Secondary objective include : - evaluation palatability user-friendliness new treatment , - evaluation pharmacokinetic parameter new formulation , - PK parameter , - evaluation tolerance , - measurement taurine plasma level . This study recruit 40 patient infantile spasm pharmacoresistant partial epilepsy age 1 month 6 year 23 clinical site France .</brief_summary>
	<brief_title>Acceptability Study New Paediatric Form Vigabatrin Infants Children With Infantile Spasms Pharmacoresistant Partial Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Spasm</mesh_term>
	<mesh_term>Muscle Cramp</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Spasms , Infantile</mesh_term>
	<mesh_term>Vigabatrin</mesh_term>
	<criteria>Patients diagnose infantile spasm ( IS ) pharmacoresistant partial onset seizure ( POS ) . Infants &gt; 1 month &lt; 6 month ; infant &gt; 6 month &lt; 2 year ; child &gt; 2 year &lt; 6 year . Patients Sabril® naive patient . Patients twiceaday posology Sabril® patient vigabatrin give twice daily . Non inclusion Criteria : Use 2 antiepileptic drug concomitant treatment ( include steroid ) . Ketogenic diet addition 2 antiepileptic drug . Subjects receive vigabatrin gastric tube . Weight &lt; 1.750 Kgs . Any plan major surgery within duration trial . Participation clinical trial within 3 month prior V1 .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Infantile spasm</keyword>
	<keyword>vigabatrin</keyword>
	<keyword>soluble tablet</keyword>
	<keyword>acceptability</keyword>
	<keyword>adherence</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>